Provided by Tiger Trade Technology Pte. Ltd.

Plus Therapeutics, Inc.

0.2599
+0.026011.12%
Post-market: 0.2500-0.0099-3.81%19:59 EST
Volume:8.49M
Turnover:2.06M
Market Cap:46.36M
PE:-0.57
High:0.2599
Open:0.2300
Low:0.2223
Close:0.2339
52wk High:2.31
52wk Low:0.1634
Shares:178.37M
Float Shares:178.37M
Volume Ratio:0.89
T/O Rate:4.76%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4560
EPS(LYR):-1.9544
ROE:-522.50%
ROA:-65.58%
PB:9.17
PE(LYR):-0.13

Loading ...

Plus Therapeutics (PSTV) Gets a Buy from Lake Street

TIPRANKS
·
Feb 05

Plus Therapeutics initiated with a Buy at Lake Street

TIPRANKS
·
Feb 03

Maxim Group Sticks to Their Buy Rating for Plus Therapeutics (PSTV)

TIPRANKS
·
Jan 23

Plus Therapeutics announces anticipated milestones for FY26

TIPRANKS
·
Jan 22

Plus Therapeutics Inc - Reyobiq Phase 2 Trial Data Expected in Q3 2026

THOMSON REUTERS
·
Jan 22

BRIEF-Plus Therapeutics To Provide Business Update On Thursday

Reuters
·
Jan 22

Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET

GlobeNewswire
·
Jan 22

Benzinga Bulls And Bears: TSMC, Rocket Lab, J.B. Hunt — And Space Stocks Soar

Benzinga_recent_news
·
Jan 17

BRIEF-Plus Therapeutics Inc - On Jan 13, Co Enters Underwriting Agreement With Lake Street Capital Markets, Llc - SEC Filing

Reuters
·
Jan 17

Plus Therapeutics Inc - to Issue 39,473,684 Shares and Warrants at $0.38 Each - SEC Filing

THOMSON REUTERS
·
Jan 17

Plus Therapeutics Prices Upsized $15 Million Public Offering

MT Newswires Live
·
Jan 15

Crude Oil Gains Over 1%; US Retail Sales Rise 0.6% In November

Benzinga
·
Jan 15

Penny Cancer Stock Plus Therapeutics Raises $15 Million At Discount, Stock Plunges

Benzinga_recent_news
·
Jan 15

Plus Therapeutics prices 39.5M units at 38c in upsized public offering

TIPRANKS
·
Jan 14

Plus Therapeutics Inc - Each Unit Sold at $0.38, Gross Proceeds Expected $15 Mln

THOMSON REUTERS
·
Jan 14

Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering

GlobeNewswire
·
Jan 14

BRIEF-Plus Therapeutics Announces Read Out Of Type B Meeting With The FDA

Reuters
·
Jan 08

Plus Therapeutics Announces Read Out of Type B Meeting With the FDA With Goal of Accelerating Approval of Reyobiq™ for Leptomeningeal Metastases

THOMSON REUTERS
·
Jan 08

Plus Therapeutics Inc - FDA Recommends Study Evaluate Endpoint With Clinical Benefit

THOMSON REUTERS
·
Jan 08

Plus Therapeutics Inc - FDA Indicates Accelerated Approval May Be Appropriate for Lm

THOMSON REUTERS
·
Jan 08